Experimental CAR-T therapy takes on tough leukemia

NCT ID NCT07233018

Not yet recruiting Disease control Sponsor: MEI HENG Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called CT0991, which uses a patient's own immune cells engineered to attack leukemia cells. It will enroll 24 adults with acute myeloid leukemia that has returned or not responded to standard therapy. The main goals are to check safety, find the right dose, and look for signs that the cancer shrinks or disappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT0991 CAR-T cells
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.